← Leaderboards
Gary E. Landreth
Indiana University Indianapolis
$21,167,585
Attributed
$29,278,118
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,528,030 · 19
By mechanism
R01$13,489,929 · 8
RF1$11,616,441 · 5
P50$2,857,814 · 2
T32$2,338,602 · 1
K07$809,410 · 1
R56$395,313 · 1
Top collaborators
- Bruce T Lamb10 shared
- Andrew J Saykin5 shared
- Harris Goldstein4 shared
- Brandon K Harvey4 shared
- Jonathan Karn4 shared
- Stephanie J Bissel3 shared
- Richard M Ransohoff2 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Cristine L Czachowski$12,752,828
- Zheng-Ming Ding$2,488,005
- Eric A. Engleman$2,091,379
- Frederic Woodward Hopf$8,663,928
- Anna M McDaniel$2,087,362
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposMicrogliaS DiseaseBrainReceptorS Disease ModelMediatingPathogenesisPathologyAgonistComplexCellsExhibitsNeuronsNuclear ReceptorsAffectDisease ProgressionAnimal ModelCognitionMouse ModelPeroxisome Proliferator-Activated ReceptorsReportingPreventLigands
Grant awards (58)
Impact of PLCG2 Alzheimer's Disease Risk Variants on Microglia Biology and Disease Pathogenesis$730,718
R01 · FY2025 · AG
Repurposing FDA-approved agonists of HCAR2 as novel therapeutics for Alzheimer's Disease$547,852
R01 · FY2025 · AG · contact PI
Training Grant on Alzheimer's Disease and ADRD at Indiana University$279,485
T32 · FY2025 · AG · contact PI
Impact of PLCG2 Alzheimer's Disease Risk Variants on Microglia Biology and Disease Pathogenesis$753,556
R01 · FY2024 · AG
Training Grant on Alzheimer's Disease and ADRD at Indiana University$546,393
T32 · FY2024 · AG · contact PI
Microglial hexokinase 2 as a therapeutic target in Alzheimer's disease$508,872
R01 · FY2024 · AG · contact PI
Academic Leadership Award at the Indiana University School of Medicine$161,882
K07 · FY2024 · AG · contact PI
Training Grant on Alzheimer's Disease and ADRD at Indiana University$512,594
T32 · FY2023 · AG · contact PI
Academic Leadership Award at the Indiana University School of Medicine$161,882
K07 · FY2023 · AG · contact PI
Repurposing FDA-approved agonists of HCAR2 as novel therapeutics for Alzheimer's Disease$1,691,548
RF1 · FY2022 · AG · contact PI
Training Grant on Alzheimer's Disease and ADRD at Indiana University$494,484
T32 · FY2022 · AG · contact PI
Academic Leadership Award at the Indiana University School of Medicine$161,882
K07 · FY2022 · AG · contact PI
Impact of PLCG2 Alzheimer's Disease Risk Variants on Microglia Biology and Disease Pathogenesis$2,333,674
RF1 · FY2021 · AG
Training Grant on Alzheimer's Disease and ADRD at Indiana University$505,646
T32 · FY2021 · AG · contact PI
Academic Leadership Award at the Indiana University School of Medicine$161,882
K07 · FY2021 · AG · contact PI
Microglial hexokinase 2 as a therapeutic target in Alzheimer's disease$2,043,711
RF1 · FY2020 · AG · contact PI
Academic Leadership Award at the Indiana University School of Medicine$161,882
K07 · FY2020 · AG · contact PI
Functional Significance of Amyloid Dynamics and Deposition in the AD Brain$282,649
R01 · FY2017 · AG · contact PI
Actions of Nuclear Receptors on TREM2+ myeloid cells and microglia in AD brain$1,649,492
RF1 · FY2016 · AG · contact PI
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$708,347
R01 · FY2016 · DA
Actions of Nuclear Receptors on TREM2+ myeloid cells and microglia in AD brain$331,758
RF1 · FY2016 · AG · contact PI
Functional Significance of Amyloid Dynamics and Deposition in the AD Brain$211,122
R01 · FY2016 · AG · contact PI
Functional significance of amyloid dynamics and deposition in the AD brain$113,803
R01 · FY2016 · AG · contact PI
Central and Peripheral Roles of TREM2 in Alzheimer's Disease$3,528,849
RF1 · FY2015 · AG
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$706,181
R01 · FY2015 · DA
Functional significance of amyloid dynamics and deposition in the AD brain$315,177
R01 · FY2015 · AG · contact PI
Central and Peripheral Roles of TREM2 in Alzheimer's Disease$37,409
RF1 · FY2015 · AG
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$718,338
R01 · FY2014 · DA
Functional significance of amyloid dynamics and deposition in the AD brain$324,925
R01 · FY2014 · AG · contact PI
Drugs of abuse and the epigenetic and signaling pathways controlling HIV latency$734,339
R01 · FY2013 · DA
Nuclear Receptors as Therapeutic Targets in AD$395,313
R56 · FY2013 · NS · contact PI
Functional significance of amyloid dynamics and deposition in the AD brain$324,925
R01 · FY2013 · AG · contact PI
LXR and PPARgamma mediated Abeta clearance mechanisms$295,364
R01 · FY2011 · AG · contact PI
LXR and PPARgamma mediated Abeta clearance mechanisms$462,717
R01 · FY2010 · AG · contact PI
Microglial Signaling Mechanisms in Alzheimer's Disease$268,538
R01 · FY2010 · AG · contact PI
LXR and PPARgamma mediated Abeta clearance mechanisms$310,391
R01 · FY2009 · AG · contact PI
Microglial Signaling Mechanisms in Alzheimer's Disease$271,251
R01 · FY2009 · AG · contact PI
LXR and PPARgamma mediated Abeta clearance mechanisms$157,000
R01 · FY2009 · AG · contact PI
LXR and PPARgamma mediated Abeta clearance mechanisms$310,391
R01 · FY2008 · AG · contact PI
Microglial Signaling Mechanisms in Alzheimer's Disease$271,251
R01 · FY2008 · AG · contact PI
LXR and PPARgamma mediated Abeta clearance mechanisms$316,725
R01 · FY2007 · AG · contact PI
Microglial Signaling Mechanisms in Alzheimer's Disease$276,787
R01 · FY2007 · AG · contact PI
Liver X Receptors as Therapeutic Targets in Alzheimer?s Disease$20,521
R21 · FY2007 · AG · contact PI
Microglial Signaling Mechanisms in Alzheimer's Disease$285,053
R01 · FY2006 · AG · contact PI
Mechanisms of Microglial Activation and Phagocytosis in*$344,250
R01 · FY2005 · AG
UHC/CWRU ALZHEIMER'S DISEASE RESEARCH CENTER$2,249,912
P50 · FY2004 · AG
Mechanisms of Microglial Activation and Phagocytosis in*$344,250
R01 · FY2004 · AG
MICROGLIAL SIGNALING MECHANISMS IN ALZHEIMER'S DISEASE$330,206
R01 · FY2004 · AG
Mechanisms of Microglial Activation and Phagocytosis in*$344,250
R01 · FY2003 · AG
MICROGLIAL SIGNALING MECHANISMS IN ALZHEIMER'S DISEASE$320,593
R01 · FY2003 · AG
Mechanisms of Microglial Activation and Phagocytosis in*$344,250
R01 · FY2002 · AG
MICROGLIAL SIGNALING MECHANISMS IN ALZHEIMER'S DISEASE$311,251
R01 · FY2002 · AG
Abortive Cell Cycle Reentry and Neuronal Apoptosis in AD$202,634
P50 · FY2002 · AG
Microglial Activation and Phagocytosis in Alzheimers$344,250
R01 · FY2001 · AG
MICROGLIAL SIGNALING MECHANISMS IN ALZHEIMER'S DISEASE$302,186
R01 · FY2001 · AG
Abortive Cell Cycle Reentry and Neuronal Apoptosis in AD$202,634
P50 · FY2001 · AG
MICROGLIAL SIGNALING MECHANISMS IN ALZHEIMER'S DISEASE$298,171
R01 · FY2000 · AG
Abortive Cell Cycle Reentry and Neuronal Apoptosis in AD$202,634
P50 · FY2000 · AG